{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:54:55Z","timestamp":1794002095572,"version":"4.8.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.euo.2025.09.006","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:37:06Z","timestamp":1760002626000},"page":"168-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-0598","authenticated-orcid":false,"given":"Javier","family":"Molina-Cerrillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.09.006_b0005","unstructured":"European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer. 2025. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer."},{"key":"10.1016\/j.euo.2025.09.006_b0010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.09.006_b0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: a systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.09.006_b0020","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.09.006_b0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.09.006_b0030","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.09.006_b0035","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/annonc\/mdu126","volume":"25","author":"Kitamura","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2025.09.006_b0045","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2023.06.014","article-title":"Long-term outcomes from a phase 2 study of neoadjuvant chemotherapy for muscle-invasive bladder cancer (SWOG S1314; NCT02177695)","volume":"84","author":"Flaig","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.09.006_b0055","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.09.006_b0060","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0065","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.euo.2025.09.006_b0070","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.euo.2025.09.006_b0075","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","article-title":"Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial","volume":"16","author":"Carthon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.09.006_b0080","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0085","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.09.006_b0090","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1186\/s12885-021-08990-3","article-title":"Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)","volume":"21","author":"Martinez Chanza","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2025.09.006_b0095","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.09.006_b0100","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.09.006_b0105","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1200\/JCO.2020.38.15_suppl.5012","article-title":"DUTRENEO trial: a randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature","volume":"38","author":"Grande","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0110","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.euo.2025.09.006_b0115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.euo.2025.09.006_b0120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.euo.2025.09.006_b0125","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2022.40.16_suppl.4515","article-title":"Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Primary analysis of the single arm phase II trial SAKK 06\/17","volume":"40","author":"Cathomas","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0130","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial","volume":"40","author":"Funt","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0135","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1200\/JCO.24.00576","article-title":"First results of NURE-Combo: a phase II study of neoadjuvant nivolumab and nab-paclitaxel, followed by postsurgical adjuvant nivolumab, for muscle-invasive bladder cancer","volume":"42","author":"Mercinelli","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0140","unstructured":"FDA. FDA approves durvalumab for muscle invasive bladder cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-muscle-invasive-bladder-cancer."},{"key":"10.1016\/j.euo.2025.09.006_b0145","unstructured":"EMA. Imfinzi: durvalumab. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imfinzi."},{"key":"10.1016\/j.euo.2025.09.006_b0150","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0155","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.09.006_b0160","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euo.2023.09.011","article-title":"Pembrolizumab with chemoradiation as treatment for muscle-invasive bladder cancer: analysis of safety and efficacy of the PCR-MIB phase 2 clinical trial (ANZUP 1502)","volume":"7","author":"Weickhardt","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0165","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1078-0432.CCR-24-2636","article-title":"Bladder preservation with durvalumab plus tremelimumab and concurrent radiotherapy in patients with localized muscle-invasive bladder cancer (IMMUNOPRESERVE): a phase II Spanish Oncology GenitoUrinary Group trial","volume":"31","author":"Garcia-del-Muro","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.09.006_b0170","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS890","article-title":"NEO-BLAST: neoadjuvant therapy for bladder cancer followed by active surveillance vs treatment","volume":"43","author":"St-Laurent","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0175","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0180","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2023.41.6_suppl.448","article-title":"HCRN GU14-188: phase Ib\/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer","volume":"41","author":"Brown","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0185","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.09.006_b0190","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2025.43.16_suppl.4594","article-title":"Overall survival and biomarker results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC)","volume":"43","author":"Mercinelli","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0195","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1200\/JCO.2025.43.16_suppl.4518","article-title":"First results of SURE-02: A phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC)","volume":"43","author":"Necchi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0200","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1200\/JCO.2025.43.16_suppl.4583","article-title":"Study EV-103 cohort H: neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)\u20143-year efficacy results","volume":"43","author":"Mar","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0205","article-title":"Phase 3 KEYNOTE-905\/EV-303: Perioperative pembrolizumab (pembro) or pembro\u00a0+\u00a0enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC)","volume":"41","author":"Necchi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0210","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4587","article-title":"KEYNOTE-B15\/EV-304: randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC)","volume":"39","author":"Hoimes","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0215","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS579","article-title":"A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D)\u00a0+\u00a0tremelimumab (T)\u00a0+\u00a0enfortumab vedotin (EV) or D\u00a0+\u00a0EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA)","volume":"40","author":"Powles","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0220","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1200\/JCO.2025.43.16_suppl.4519","article-title":"9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripalimab in treatment-na\u00efve patients with locally advanced or metastatic urothelial carcinoma (la\/mUC): results from a phase 1b\/2 study","volume":"43","author":"Jiang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0225","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1200\/JCO.2025.43.16_suppl.4567","article-title":"Phase 1\/2 duravelo-1 study: preliminary results of nectin-4\u2013targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"43","author":"Giannatempo","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0230","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.2025.43.5_suppl.726","article-title":"Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment for patients with locally advanced muscle-invasive bladder cancer: a mono-institutional retrospective study","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0235","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1200\/JCO.2025.43.16_suppl.4520","article-title":"CLONEVO: preoperative abemaciclib for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) with molecular response assessment","volume":"43","author":"Faltas","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0240","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS712","article-title":"Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (GDFather-Neo)","volume":"42","author":"Necchi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0245","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS599","article-title":"Randomized phase 2 umbrella study of various neoadjuvant therapies for patients with muscle-invasive urothelial carcinoma of the bladder (MIBC) who are cisplatin-ineligible or refuse cisplatin therapy and undergoing radical cystectomy (Optimus)","volume":"40","author":"Necchi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0250","unstructured":"Johnson & Johnson. Statement on the SunRISe-2 study. https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-statement-on-the-sunrise-2-study."},{"key":"10.1016\/j.euo.2025.09.006_b0255","doi-asserted-by":"crossref","first-page":"S1271","DOI":"10.1016\/j.annonc.2024.08.2328","article-title":"LBA84 TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): interim analysis of SunRISe-4 (SR-4)","volume":"35","author":"Necchi","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0260","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12967-024-04860-1","article-title":"Single-cell sequencing reveals the heterogeneity of B cells and tertiary lymphoid structures in muscle-invasive bladder cancer","volume":"22","author":"Yuan","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.euo.2025.09.006_b0265","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-023-01425-5","article-title":"APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential","volume":"16","author":"Butler","year":"2023","journal-title":"J Hematol Oncology"},{"key":"10.1016\/j.euo.2025.09.006_b0270","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","article-title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.09.006_b0275","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO-24-01214","article-title":"Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)","volume":"43","author":"Geynisman","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0280","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.12363","article-title":"Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial","volume":"10","author":"Griffin","year":"2024","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.euo.2025.09.006_b0285","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1158\/0008-5472.CAN-22-1444","article-title":"KDM6A loss triggers an epigenetic switch that disrupts urothelial differentiation and drives cell proliferation in bladder cancer","volume":"83","author":"Qiu","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2025.09.006_b0290","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s11255-023-03841-5","article-title":"Multi-omics analysis reveals critical metabolic regulators in bladder cancer","volume":"56","author":"Wei","year":"2024","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euo.2025.09.006_b0295","doi-asserted-by":"crossref","first-page":"S1133","DOI":"10.1016\/j.annonc.2024.08.2045","article-title":"1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial","volume":"35","author":"Bjerggaard Jensen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0300","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.09.006_b0305","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11934-025-01264-6","article-title":"Management of patients with muscle-invasive bladder cancer achieving a clinical complete response after neoadjuvant therapy: evidence and consideration for active surveillance","volume":"26","author":"Joffe","year":"2025","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.euo.2025.09.006_b0310","doi-asserted-by":"crossref","first-page":"144","DOI":"10.23736\/S2724-6051.19.03648-8","article-title":"The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"73","author":"Liu","year":"2021","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.euo.2025.09.006_b0315","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.09.006_b0320","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00262-024-03651-3","article-title":"Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.euo.2025.09.006_b0325","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/bju.16695","article-title":"Understanding patient perspectives in the management of their muscle-invasive bladder cancer","volume":"136","author":"Chowdhury","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.09.006_b0330","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233020","article-title":"Neoadjuvant chemotherapy VI-RADS scores for assessing muscle-invasive bladder cancer response to neoadjuvant immunotherapy with multiparametric MRI","volume":"313","author":"Brembilla","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.euo.2025.09.006_b0335","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bju.16242","article-title":"Health-related quality of life after a diagnosis of bladder cancer: a longitudinal survey over the first year","volume":"133","author":"Rogers","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.09.006_b0340","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","article-title":"Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes","volume":"79","author":"Catto","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.09.006_b0345","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043266","article-title":"Short-term morbidity and mortality following radical cystectomy: a systematic review","volume":"11","author":"Maibom","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.euo.2025.09.006_b0350","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1200\/EDBK_201227","article-title":"Multidisciplinary management of muscle-invasive bladder cancer: current challenges and future directions","volume":"38","author":"Aragon-Ching","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.euo.2025.09.006_b0355","first-page":"697","article-title":"Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer","volume":"17","author":"Ericson","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0360","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11934-019-0949-6","article-title":"Variant histology in bladder cancer-current understanding of pathologic subtypes","volume":"20","author":"Aron","year":"2019","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.euo.2025.09.006_b0365","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.006_b0370","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.09.006_b0375","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12967-025-06139-5","article-title":"The clinical application of artificial intelligence in cancer precision treatment","volume":"23","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.euo.2025.09.006_b0380","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2025.09.006_b0385","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sj\u00f6dahl","year":"2017","journal-title":"J Pathol"},{"key":"10.1016\/j.euo.2025.09.006_b0390","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.09.006_b0395","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.2020.38.6_suppl.507","article-title":"Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2","volume":"38","author":"Wei","year":"2020","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1016\/j.euo.2025.09.006","type":"removal","label":"Removal","source":"publisher","updated":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000}}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:56:45Z","timestamp":1775681805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125002421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2588931125002421"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.09.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}